S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
S&P 500   4,330.00 (-1.64%)
DOW   34,070.42 (-1.08%)
QQQ   357.86 (-1.83%)
AAPL   173.93 (-0.89%)
MSFT   319.53 (-0.39%)
META   295.73 (-1.31%)
GOOGL   130.44 (-2.47%)
AMZN   129.33 (-4.41%)
TSLA   255.70 (-2.62%)
NVDA   410.17 (-2.89%)
NIO   8.46 (-4.19%)
BABA   84.12 (-1.89%)
AMD   96.11 (-4.22%)
T   15.31 (-1.61%)
F   12.20 (-1.30%)
MU   67.90 (-2.55%)
CGC   0.77 (-11.53%)
GE   112.97 (-1.64%)
DIS   82.73 (+0.21%)
AMC   7.71 (-5.51%)
PFE   32.85 (-2.29%)
PYPL   58.62 (-3.68%)
NFLX   384.15 (-0.56%)
NASDAQ:INMD

InMode (INMD) Stock Forecast, Price & News

$32.25
-0.82 (-2.48%)
(As of 09/21/2023 ET)
Compare
Today's Range
$32.08
▼
$32.93
50-Day Range
$32.25
▼
$46.04
52-Week Range
$26.10
▼
$48.25
Volume
1.15 million shs
Average Volume
1.44 million shs
Market Capitalization
$2.68 billion
P/E Ratio
15.07
Dividend Yield
N/A
Price Target
$51.67
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesShort InterestSocial Media

InMode MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
60.2% Upside
$51.67 Price Target
Short Interest
Bearish
9.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.39mentions of InMode in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
15.51%
From $2.45 to $2.83 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.46 out of 5 stars

Medical Sector

162nd out of 961 stocks

Electromedical Equipment Industry

3rd out of 22 stocks

See Top Rated MarketRank™ Stocks Here

INMD stock logo

About InMode (NASDAQ:INMD) Stock

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

INMD Price History

INMD Stock News Headlines

September 20, 2023 | finance.yahoo.com
Is Most-Watched Stock InMode Ltd. (INMD) Worth Betting on Now?
September 16, 2023 | americanbankingnews.com
InMode Ltd. (NASDAQ:INMD) Given Average Recommendation of "Moderate Buy" by Brokerages
September 21, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
September 6, 2023 | finance.yahoo.com
InMode Ltd. (INMD) is Attracting Investor Attention: Here is What You Should Know
September 4, 2023 | finance.yahoo.com
Is HealthEquity (HQY) Outperforming Other Medical Stocks This Year?
September 4, 2023 | seekingalpha.com
InMode: Be Greedy When Others Are Fearful
August 24, 2023 | msn.com
InMode: Prolonged Valuation Slump Is A Buying Opportunity
August 18, 2023 | finance.yahoo.com
InMode Ltd. (INMD) Is a Trending Stock: Facts to Know Before Betting on It
September 21, 2023 | Chaikin Analytics (Ad)
His system isolated NVIDIA - Here's His Next Buy.
Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.
August 11, 2023 | finance.yahoo.com
Got $5,000? Here's 3 Reasons to Buy InMode Stock Right Now
August 9, 2023 | msn.com
This 1 Number Shows Why InMode Stock Is a Buy
August 2, 2023 | msn.com
Inmode (INMD) Price Target Increased by 17.87% to 56.51
August 1, 2023 | finance.yahoo.com
Here's Why We Think InMode (NASDAQ:INMD) Might Deserve Your Attention Today
July 29, 2023 | finance.yahoo.com
Here's Why I'm Buying (More) InMode Stock in August
July 28, 2023 | msn.com
Baird Maintains Inmode (INMD) Outperform Recommendation
July 28, 2023 | finance.yahoo.com
InMode Ltd. (NASDAQ:INMD) Q2 2023 Earnings Call Transcript
July 28, 2023 | finance.yahoo.com
InMode (INMD) Q2 2023 Earnings Call Transcript
July 27, 2023 | finance.yahoo.com
InMode Reports Second Quarter 2023 Financial Results; Record Quarterly Revenue of $136.1M Represents 20% Year-Over-Year Growth
July 27, 2023 | finance.yahoo.com
InMode (INMD) Q2 Earnings and Revenues Beat Estimates
July 27, 2023 | finance.yahoo.com
Are Medical Stocks Lagging InMode (INMD) This Year?
July 25, 2023 | finance.yahoo.com
InMode (INMD) to Post Q2 Earnings: What's in the Cards?
July 19, 2023 | finance.yahoo.com
Investors Heavily Search InMode Ltd. (INMD): Here is What You Need to Know
July 18, 2023 | finance.yahoo.com
Institutional investors control 62% of InMode Ltd. (NASDAQ:INMD) and were rewarded last week after stock increased 13%
July 18, 2023 | seekingalpha.com
InMode: A Laser-Focused Investment Opportunity
July 13, 2023 | finance.yahoo.com
InMode (INMD) Stock Sinks As Market Gains: What You Should Know
July 13, 2023 | markets.businessinsider.com
Barclays Sticks to Their Buy Rating for InMode (INMD)
July 12, 2023 | benzinga.com
Babylon Capital® Quality & Valuation Analysis On Inmode | Why Inmode Deserves To Be In Your Watchlist
See More Headlines
Receive INMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMode and its competitors with MarketBeat's FREE daily newsletter.

INMD Company Calendar

Last Earnings
7/27/2023
Today
9/21/2023
Next Earnings (Estimated)
10/26/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Electromedical equipment
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INMD
CUSIP
N/A
CIK
885988
Web
www.inmodemd.com
Phone
972-4909-7470
Fax
N/A
Employees
480
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$51.67
High Stock Price Forecast
$61.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+56.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$2.14
Trailing P/E Ratio
15.45
Forward P/E Ratio
13.50
P/E Growth
N/A
Net Income
$161.52 million
Net Margins
36.77%
Pretax Margin
44.98%
Return on Equity
35.03%
Return on Assets
31.10%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
11.84
Quick Ratio
11.21

Sales & Book Value

Annual Sales
$454.27 million
Price / Sales
6.04
Cash Flow
$2.17 per share
Price / Cash Flow
15.25
Book Value
$6.68 per share
Price / Book
4.95

Miscellaneous

Outstanding Shares
82,980,000
Free Float
77,236,000
Market Cap
$2.74 billion
Optionable
Not Optionable
Beta
2.11

Social Links

7 Stocks to Buy And Hold Forever Cover
7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Yair Malca (Age 45)
    Chief Financial Officer
    Comp: $474k
  • Mr. Alon Yaari
    VP of Operations
  • Dr. Michael Kreindel (Age 55)
    CTO & Director
    Comp: $221k
  • Ms. Nava Tal-Launer
    Chief Information Officer
  • Mr. Shakil Lakhani (Age 40)
    Pres of North America
    Comp: $2.97M
  • Mr. Moshe Mizrahy (Age 70)
    Chairman & CEO
  • Dr. Spero Theodorou M.D. (Age 51)
    Chief Medical Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













INMD Stock - Frequently Asked Questions

Should I buy or sell InMode stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InMode in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" INMD shares.
View INMD analyst ratings or view top-rated stocks.

What is InMode's stock price forecast for 2023?

6 brokerages have issued 1 year price objectives for InMode's shares. Their INMD share price forecasts range from $40.00 to $61.00. On average, they anticipate the company's stock price to reach $51.67 in the next year. This suggests a possible upside of 56.2% from the stock's current price.
View analysts price targets for INMD or view top-rated stocks among Wall Street analysts.

How have INMD shares performed in 2023?

InMode's stock was trading at $35.70 on January 1st, 2023. Since then, INMD shares have decreased by 7.4% and is now trading at $33.07.
View the best growth stocks for 2023 here.

When is InMode's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our INMD earnings forecast.

How were InMode's earnings last quarter?

InMode Ltd. (NASDAQ:INMD) issued its earnings results on Thursday, July, 27th. The healthcare company reported $0.65 earnings per share for the quarter, meeting the consensus estimate of $0.65. The healthcare company earned $136.08 million during the quarter, compared to analyst estimates of $135.80 million. InMode had a trailing twelve-month return on equity of 35.03% and a net margin of 36.77%.

What ETFs hold InMode's stock?

ETFs with the largest weight of InMode (NASDAQ:INMD) stock in their portfolio include The Acquirers Fund (ZIG), BlueStar Israel Technology ETF (ITEQ), ARK Israel Innovative Technology ETF (IZRL), VanEck Israel ETF (ISRA) and iShares MSCI Israel ETF (EIS).Vident International Equity Strategy ETF (VIDI).

When did InMode's stock split?

InMode's stock split on Thursday, September 30th 2021. The 2-1 split was announced on Friday, September 17th 2021. The newly created shares were payable to shareholders after the closing bell on Monday, September 27th 2021. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What guidance has InMode issued on next quarter's earnings?

InMode updated its FY23 earnings guidance on Thursday, July, 27th. The company provided earnings per share (EPS) guidance of $2.62-$2.66 for the period, compared to the consensus estimate of $2.64. The company issued revenue guidance of $530-$540 million, compared to the consensus revenue estimate of $534.01 million.

What is Moshe Mizrahy's approval rating as InMode's CEO?

1 employees have rated InMode Chief Executive Officer Moshe Mizrahy on Glassdoor.com. Moshe Mizrahy has an approval rating of 100% among the company's employees. This puts Moshe Mizrahy in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of InMode own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InMode investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Micron Technology (MU), AbbVie (ABBV), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), DocuSign (DOCU) and PayPal (PYPL).

When did InMode IPO?

(INMD) raised $75 million in an initial public offering (IPO) on Thursday, August 8th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. ​Barclays, UBS Investment Bank and Canaccord Genuity served as the underwriters for the IPO and Baird was co-manager.

What is InMode's stock symbol?

InMode trades on the NASDAQ under the ticker symbol "INMD."

Who are InMode's major shareholders?

InMode's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.56%), Acadian Asset Management LLC (3.55%), Renaissance Technologies LLC (2.89%), State Street Corp (2.09%), William Blair Investment Management LLC (1.76%) and Meitav Investment House Ltd. (1.21%).

How do I buy shares of InMode?

Shares of INMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InMode's stock price today?

One share of INMD stock can currently be purchased for approximately $33.07.

How much money does InMode make?

InMode (NASDAQ:INMD) has a market capitalization of $2.74 billion and generates $454.27 million in revenue each year. The healthcare company earns $161.52 million in net income (profit) each year or $2.14 on an earnings per share basis.

How many employees does InMode have?

The company employs 480 workers across the globe.

Does InMode have any subsidiaries?
The following companies are subsidiares of InMode: Guangzhou InMode Medical Technology Ltd., InMode Asia Limited., InMode India Private Limited, InMode Japan KK, InMode M.D. Ltd., Invasix Corp., Invasix Iberia S.L., Invasix Inc., and Invasix UK Ltd..
Read More
How can I contact InMode?

InMode's mailing address is TAVOR BUILDING SHAAR YOKNEAM POB 533, YOKNEAM L3, 2069200. The official website for the company is www.inmodemd.com. The healthcare company can be reached via phone at 972-4909-7470 or via email at ir@inmodemd.com.

This page (NASDAQ:INMD) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -